{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:40:39Z","timestamp":1787010039390,"version":"build-2736575974"},"reference-count":67,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/ http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Chronic pruritus is a debilitating condition affecting 23\u201344 million Americans. Recently, kappa opioid agonists (KOAs) have emerged as a novel class of potent antipruritic agents. In 2021, the Food and Drug Administration approved difelikefalin (Korsuva) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. Difelikefalin is a potent, peripherally restricted KOA that is intravenously available. Although promising, difelikefalin is currently available as an intravenous composition only, limiting the scope of use. Oral formulations of difelikefalin did not meet the primary endpoint criteria in recent phase 2 clinical trials; however, additional clinical studies are ongoing. The future for KOAs in the treatment of pruritus is encouraging. Orally active pathway-biased KOAs, such as triazole 1.1, may serve as viable alternatives with broader applications. Extended-release compositions, such as the TP-2021 ProNeura subdermal implant, may circumvent the pharmacokinetic issues associated with peptide-based KOAs. Lastly, dual-acting kappa opioid receptor agonist\/mu opioid receptor antagonists are orally bioavailable and may be useful in the treatment of various forms of chronic itch. In this review, we summarize the results of KOAs in clinical and preclinical trials and discuss future directions of drug development.<\/jats:p>","DOI":"10.1097\/itx.0000000000000072","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T09:03:34Z","timestamp":1701853414000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Kappa opioid agonists in the treatment of itch: just scratching the surface?"],"prefix":"10.1097","volume":"8","author":[{"given":"Tyler C.","family":"Beck","sequence":"first","affiliation":[{"name":"Department of Dermatology and Dermatological Surgery, Medical University of South Carolina, Charleston, SC"},{"name":"Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena M.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Dermatological Surgery, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Wilkes","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara Wine","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Dermatological Surgery, Medical University of South Carolina, Charleston, SC"},{"name":"Department of Pediatrics, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Norris","sequence":"additional","affiliation":[{"name":"Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Valdebran","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Dermatological Surgery, Medical University of South Carolina, Charleston, SC"},{"name":"Department of Pediatrics, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,10]]},"reference":[{"key":"R1-20240805","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/0019-5154.198036","article-title":"Diagnosis and management of chronic pruritus: an expert consensus review","volume":"62","author":"Rajagopalan","year":"2017","journal-title":"Indian J Dermatol"},{"key":"R2-20240805","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s13671-014-0093-y","article-title":"Epidemiology of chronic pruritus: where have we been and where are we going?","volume":"4","author":"N","year":"2015","journal-title":"Curr Dermatol Rep"},{"key":"R3-20240805","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s13555-019-00326-1","article-title":"Management of itch in the elderly: a review","volume":"9","author":"Fourzali","year":"2019","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R4-20240805","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/dth.12025","article-title":"Understanding the pathophysiology of itch","volume":"26","author":"Garibyan","year":"2013","journal-title":"Dermatol Ther"},{"key":"R5-20240805","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/exd.14669","article-title":"Role of kappa-opioid and mu-opioid receptors in pruritus: Peripheral and central itch circuits","volume":"31","author":"Kim","year":"2022","journal-title":"Exp Dermatol"},{"key":"R6-20240805","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/978-3-662-44605-8_13","article-title":"Protease-activated receptors and itch","volume":"226","author":"Akiyama","year":"2015","journal-title":"Handb Exp Pharmacol"},{"key":"R7-20240805","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00403-018-1809-9","article-title":"Attenuation of serotonin-induced itch by sumatriptan: possible involvement of endogenous opioids","volume":"310","author":"Haddadi","year":"2018","journal-title":"Arch Dermatol Res"},{"key":"R8-20240805","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.neuroscience.2013.07.035","article-title":"Neural processing of itch","volume":"250","author":"Akiyama","year":"2013","journal-title":"Neuroscience"},{"key":"R9-20240805","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12016-015-8488-5","article-title":"Mediators of chronic pruritus in atopic dermatitis: getting the itch out","volume":"51","author":"Mollanazar","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"R11-20240805","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2147\/CCID.S289716","article-title":"Current clinical options for the management of itch in atopic dermatitis","volume":"14","author":"Lipman","year":"2021","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R12-20240805","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40257-017-0335-4","article-title":"Management of itch in atopic dermatitis","volume":"19","author":"Pavlis","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"R13-20240805","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s004030050309","article-title":"Effect of topical capsaicin on the cutaneous reactions and itching to histamine in atopic eczema compared to healthy skin","volume":"290","author":"Weisshaar","year":"1998","journal-title":"Arch Dermatol Res"},{"key":"R14-20240805","first-page":"135","article-title":"Choosing topical corticosteroids","volume":"79","author":"Ference","year":"2009","journal-title":"Am Fam Physician"},{"key":"R15-20240805","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"R16-20240805","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40266-020-00750-5","article-title":"Atopic dermatitis in older adults: a review of treatment options","volume":"37","author":"Tanei","year":"2020","journal-title":"Drugs Aging"},{"key":"R17-20240805","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.neures.2004.07.005","article-title":"The immunosuppressant FK506 activates capsaicin- and bradykinin-sensitive DRG neurons and cutaneous C-fibers","volume":"50","author":"Senba","year":"2004","journal-title":"Neurosci Res"},{"key":"R18-20240805","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1398-9995.2005.00977.x","article-title":"Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial","volume":"61","author":"Kaufmann","year":"2006","journal-title":"Allergy"},{"key":"R19-20240805","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1365-2133.2010.09757.x","article-title":"Mechanisms of the sensory effects of tacrolimus on the skin","volume":"163","author":"Pereira","year":"2010","journal-title":"Br J Dermatol"},{"key":"R20-20240805","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40257-013-0020-1","article-title":"Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice","volume":"14","author":"Siegfried","year":"2013","journal-title":"Am J Clin Dermatol"},{"key":"R21-20240805","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2340\/00015555-0167","article-title":"Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children","volume":"87","author":"Remitz","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"R22-20240805","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/pde.12780","article-title":"Pharmacokinetic profile, safety, and tolerability of crisaborole topical ointment, 2% in adolescents with atopic dermatitis: an open-label phase 2a study","volume":"33","author":"Tom","year":"2016","journal-title":"Pediatr Dermatol"},{"key":"R23-20240805","first-page":"1236","article-title":"AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis","volume":"10","author":"Nazarian R","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"R24-20240805","first-page":"172","article-title":"Post hoc analyses of the effect of crisaborole topical ointment, 2% on atopic dermatitis: associated pruritus from phase 1 and 2 clinical studies","volume":"15","author":"Draelos","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"R25-20240805","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/pde.12872","article-title":"Crisaborole topical ointment, 2% in patients ages 2 to 17 years with atopic dermatitis: a phase 1b, open-label, maximal-use systemic exposure study","volume":"33","author":"Zane","year":"2016","journal-title":"Pediatr Dermatol"},{"key":"R26-20240805","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2340\/00015555-2893","article-title":"Early relief of pruritus in atopic dermatitis with crisaborole ointment, a non-steroidal, phosphodiesterase 4 inhibitor","volume":"98","author":"Yosipovitch","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"R27-20240805","doi-asserted-by":"crossref","first-page":"756","DOI":"10.2340\/00015555-3181","article-title":"Direct and indirect effects of crisaborole ointment on quality of life in patients with atopic dermatitis: a mediation analysis","volume":"99","author":"Simpson","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"R28-20240805","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jaad.2016.10.030","article-title":"Topical ketamine-amitriptyline-lidocaine for chronic pruritus: a retrospective study assessing efficacy and tolerability","volume":"76","author":"Lee","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R29-20240805","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"R30-20240805","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jaci.2017.04.015","article-title":"Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: a meta-analysis of randomized clinical trials","volume":"140","author":"Han","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"R31-20240805","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"R32-20240805","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2340\/0001555570323329","article-title":"Antipruritic effect of oral cyclosporin A in atopic dermatitis","volume":"70","author":"Wahlgren","year":"1990","journal-title":"Acta Derm Venereol"},{"key":"R33-20240805","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jaci.2011.03.024","article-title":"A randomized trial of methotrexate versus azathioprine for severe atopic eczema","volume":"128","author":"Schram","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"R34-20240805","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaci.2013.07.049","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review","volume":"133","author":"Roekevisch","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"R35-20240805","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1177\/120347540300700608","article-title":"Antihistamines in the treatment of dermatitis","volume":"7","author":"Herman","year":"2003","journal-title":"J Cutan Med Surg"},{"key":"R36-20240805","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/medicines6030073","article-title":"Mirtazapine for the treatment of chronic pruritus","volume":"6","author":"Khanna","year":"2019","journal-title":"Medicines (Basel)"},{"key":"R37-20240805","doi-asserted-by":"crossref","first-page":"e002838","DOI":"10.1136\/jitc-2021-002838","article-title":"JAK inhibitors and COVID-19","volume":"10","author":"Levy","year":"2022","journal-title":"J Immunother Cancer"},{"key":"R38-20240805","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"R39-20240805","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41593-018-0119-z","article-title":"Circuit dissection of the role of somatostatin in itch and pain","volume":"21","author":"Huang","year":"2018","journal-title":"Nat Neurosci"},{"key":"R40-20240805","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2222.2011.03791.x","article-title":"Basic mechanisms of itch","volume":"42","author":"Potenzieri","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"R41-20240805","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1073\/pnas.92.11.5062","article-title":"The kappa-opioid receptor is primarily postsynaptic: combined immunohistochemical localization of the receptor and endogenous opioids","volume":"92","author":"Arvidsson","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"R42-20240805","doi-asserted-by":"crossref","first-page":"ra117","DOI":"10.1126\/scisignal.aai8441","article-title":"Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria","volume":"9","author":"Brust","year":"2016","journal-title":"Sci Signal"},{"key":"R43-20240805","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1681\/ASN.2005020152","article-title":"Kappa-opioid system in uremic pruritus: multicenter, randomized, double-blind, placebo-controlled clinical studies","volume":"16","author":"Wikstrom","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"R44-20240805","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.tins.2012.05.005","article-title":"Kappa-opioid receptor\/dynorphin system: genetic and pharmacotherapeutic implications for addiction","volume":"35","author":"Butelman","year":"2012","journal-title":"Trends Neurosci"},{"key":"R45-20240805","doi-asserted-by":"crossref","first-page":"6666","DOI":"10.1073\/pnas.76.12.6666","article-title":"Dynorphin-(1-13), an extraordinarily potent opioid peptide","volume":"76","author":"Goldstein","year":"1979","journal-title":"Proc Natl Acad Sci USA"},{"key":"R46-20240805","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1006\/mcne.1994.1015","article-title":"Kappa 1 receptor mRNA distribution in the rat CNS: comparison to kappa receptor binding and prodynorphin mRNA","volume":"5","author":"Mansour","year":"1994","journal-title":"Mol Cell Neurosci"},{"key":"R47-20240805","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3389\/fimmu.2020.00300","article-title":"Opioid receptors in immune and glial cells-implications for pain control","volume":"11","author":"Machelska","year":"2020","journal-title":"Front Immunol"},{"key":"R48-20240805","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/00008571-200412000-00002","article-title":"Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of haplotypes with opiate addiction","volume":"14","author":"Yuferov","year":"2004","journal-title":"Pharmacogenetics"},{"key":"R49-20240805","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/164_2016_116","article-title":"Insights into the role of opioid receptors in the GI tract: experimental evidence and therapeutic relevance","volume":"239","author":"Galligan","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"R50-20240805","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/ph12020095","article-title":"Therapeutic potential of kappa opioid agonists","volume":"12","author":"Beck","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"key":"R51-20240805","doi-asserted-by":"crossref","first-page":"172396","DOI":"10.1016\/j.ejphar.2019.05.025","article-title":"Non-addictive orally-active kappa opioid agonists for the treatment of peripheral pain in rats","volume":"856","author":"Beck","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"R52-20240805","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/CCID.S55942","article-title":"Nalfurafine hydrochloride to treat pruritus: a review","volume":"8","author":"Inui","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R53-20240805","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/sj.bjp.0705763","article-title":"Peripheral kappa-opioid agonists for visceral pain","volume":"141","author":"Riviere","year":"2004","journal-title":"Br J Pharmacol"},{"key":"R54-20240805","first-page":"93","article-title":"Diuretic activity of a novel peripherally-restricted orally-active kappa opioid receptor agonist","volume":"7","author":"Beck","year":"2019","journal-title":"Med Sci (Basel)"},{"key":"R55-20240805","first-page":"16","article-title":"Targeting peripheral kappa opioid receptors for the treatment of chronic pain: review article","volume":"1","author":"Beck","year":"2019","journal-title":"Adv Nanomed Nanotechnol Res"},{"key":"R57-20240805","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jdin.2022.03.007","article-title":"Modulation of the kappa and mu opioid axis for the treatment of chronic pruritus: a review of basic science and clinical implications","volume":"7","author":"Elmariah","year":"2022","journal-title":"JAAD Int"},{"key":"R58-20240805","doi-asserted-by":"crossref","first-page":"e2210339","DOI":"10.1001\/jamanetworkopen.2022.10339","article-title":"Efficacy and Safety of difelikefalin in Japanese patients with moderate to severe pruritus receiving hemodialysis: a randomized clinical trial","volume":"5","author":"Narita","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R59-20240805","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1912770","article-title":"A phase 3 trial of difelikefalin in hemodialysis patients with pruritus","volume":"382","author":"Fishbane","year":"2020","journal-title":"N Engl J Med"},{"key":"R60-20240805","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/ndt\/gfp588","article-title":"Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study","volume":"25","author":"Kumagai","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"R62-20240805","doi-asserted-by":"crossref","first-page":"773204","DOI":"10.3389\/fphar.2021.773204","article-title":"Antinociceptive and Antipruritic effects of HSK21542, a peripherally-restricted kappa opioid receptor agonist, in animal models of pain and itch","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"R66-20240805","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa2210699","article-title":"Phase 2 trial of difelikefalin in notalgia paresthetica","volume":"388","author":"Kim","year":"2023","journal-title":"N Engl J Med"},{"key":"R67-20240805","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.tem.2020.08.005","article-title":"Biased opioid receptor ligands: gain without pain","volume":"31","author":"Beck","year":"2020","journal-title":"Trends Endocrinol Metab"},{"key":"R68-20240805","doi-asserted-by":"crossref","first-page":"837671","DOI":"10.3389\/fphar.2022.837671","article-title":"The kappa opioid receptor: a promising therapeutic target for multiple pathologies","volume":"13","author":"Dalefield","year":"2022","journal-title":"Front Pharmacol"},{"key":"R71-20240805","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neuroscience.2009.06.016","article-title":"Nalfurafine prevents 5\u2019-guanidinonaltrindole- and compound 48\/80-induced spinal C-fos expression and attenuates 5\u2019-guanidinonaltrindole-elicited scratching behavior in mice","volume":"163","author":"Inan","year":"2009","journal-title":"Neuroscience"},{"key":"R73-20240805","doi-asserted-by":"crossref","first-page":"143","DOI":"10.5055\/jom.2018.0441","article-title":"Does nalbuphine have a niche in managing pain","volume":"14","author":"Davis","year":"2018","journal-title":"J Opioid Manag"},{"key":"R74-20240805","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/sc.2016.28","article-title":"Evaluation of the effects of specific opioid receptor agonists in a rodent model of spinal cord injury","volume":"54","author":"Aceves","year":"2016","journal-title":"Spinal Cord"},{"key":"R75-20240805","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s13555-021-00513-z","article-title":"Gabapentinoids for pruritus in older adults: a narrative review","volume":"11","author":"Sreekantaswamy","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"R76-20240805","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb","year":"2020","journal-title":"Clin Exp Allergy"}],"container-title":["Itch"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/itx.0000000000000072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T03:07:57Z","timestamp":1722827277000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/itx.0000000000000072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":67,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/itx.0000000000000072","relation":{},"ISSN":["2380-5048"],"issn-type":[{"value":"2380-5048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"2023-06-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}